Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of intravenous FDY-5301 in acute myocardial infarction
2017-000047-41Phase 2Completed
- Sponsor
- Faraday Pharmaceuticals
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sodium iodide in myocardial infarction (MI) (4 arms), sponsored by Faraday Pharmaceuticals. Primary endpoint: Combined arrhythmia incidence over 14 days. Started Apr 2017; status: completed.
02
Drugs
Sodium iodide
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2017-000047-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000047-41.